IRTC IRhythm Technologies Inc.

iRhythm Technologies to Present at the 2024 Truist Securities MedTech Conference

iRhythm Technologies to Present at the 2024 Truist Securities MedTech Conference

SAN FRANCISCO, June 04, 2024 (GLOBE NEWSWIRE) --  (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company will be participating in the upcoming Truist Securities MedTech Conference.

iRhythm’s management is scheduled to participate in a fireside chat on Tuesday, June 18, at 9:20 a.m. Eastern Time. Interested parties may access a live and archived webcast of the event on the “Events & Presentations” section of the company’s investor website at .

About iRhythm Technologies, Inc.

iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all.

Investor Relations Contact

Stephanie Zhadkevich

Media Contact

Kassandra Perry



EN
04/06/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IRhythm Technologies Inc.

 PRESS RELEASE

iRhythm Technologies to Participate in the Citi 2024 Global Healthcare...

iRhythm Technologies to Participate in the Citi 2024 Global Healthcare Conference SAN FRANCISCO, Nov. 20, 2024 (GLOBE NEWSWIRE) --  (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company will be participating in the upcoming Citi 2024 Global Healthcare Conference. iRhythm’s management is scheduled to participate in a fireside chat on Wednesday, December 4, 2024, at 10:15 am Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Event...

 PRESS RELEASE

iRhythm Data Presented at the American Heart Association 2024 Scientif...

iRhythm Data Presented at the American Heart Association 2024 Scientific Sessions Reinforce Clinical and Health Economic Value of Zio Long-Term Continuous Monitoring Five new studies span three focus areas for LTCM devices: digital engagement and patient satisfaction, arrhythmia patterns during sleep and activity, and the potential health care resource and economic impact of early arrhythmia detection in patients with type 2 diabetes and COPD SAN FRANCISCO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC) today announced the results of five new studies presented at the American Heart As...

Irhythm Technologies Inc: 2 directors

Two Directors at Irhythm Technologies Inc bought/sold 22,809 shares at between 75.160USD and 77.410USD. The significance rating of the trade was 82/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's dir...

 PRESS RELEASE

iRhythm Technologies to Participate in the Wolfe Research 2024 Healthc...

iRhythm Technologies to Participate in the Wolfe Research 2024 Healthcare Conference SAN FRANCISCO, Nov. 05, 2024 (GLOBE NEWSWIRE) --  (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company will be participating in the upcoming Wolfe Research 2024 Healthcare Conference. iRhythm’s management is scheduled to participate in a fireside chat on Tuesday, November 19, at 9:50 am Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Events ...

 PRESS RELEASE

iRhythm Technologies Receives FDA 510(k) Clearance for Design Modifica...

iRhythm Technologies Receives FDA 510(k) Clearance for Design Modifications to Its Zio® AT Device Zio AT device, along with the Zio ECG Utilization Software (ZEUS) (K222389), enables the provision of ambulatory Mobile Cardiac Telemetry (MCT) monitoring service for non-critical care patients FDA 510(k)-cleared enhancements will be available in 2025 SAN FRANCISCO, Oct. 30, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the U.S. Food and Drug Administrat...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch